|
Neurogene Inc (NASDAQ: NGNE) |
|
Price: $20.4600
$-2.84
-12.189%
|
Day's High:
| $23.7
| Week Perf:
| 21.5 %
|
Day's Low: |
$ 19.82 |
30 Day Perf: |
-6.4 % |
Volume (M): |
315 |
52 Wk High: |
$ 74.49 |
Volume (M$): |
$ 6,435 |
52 Wk Avg: |
$35.66 |
Open: |
$23.06 |
52 Wk Low: |
$14.42 |
|
|
Market Capitalization (Millions $) |
347 |
Shares
Outstanding (Millions) |
17 |
Employees |
50 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-56 |
Cash Flow (TTM) (Millions $) |
-2 |
Capital Exp. (TTM) (Millions $) |
1 |
Neurogene Inc
Company Address: 535 W 24th St. New York 10011 NY
Company Phone Number: 508-3568 Stock Exchange / Ticker: NASDAQ NGNE
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Business Update
Published Tue, Nov 19 2024 5:10 AM UTC
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates In an era where the convergence of cutting-edge science and innovative business models is reshaping the landscape of biotechnology, Neurogene Inc. (Nasdaq: NGNE) stands at the forefront, dedicated to transforming the lives of patients afflicted with rare neurological diseases through pione...
|
Business Update
Published Mon, Nov 18 2024 12:47 PM UTC
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome In a significant era for genetic medicine, Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotech company focused on addressing the needs of patients with rare neurological diseases, is making strides in its Phase 1/2 open-label clinical trial for NGN-401, a gene therapy targeting Rett syndro...
|
Business Update
Published Tue, Nov 12 2024 3:36 AM UTC
In a significant milestone for pediatric neurology, Neurogene Inc. has announced positive interim efficacy data from the first four low-dose participants in its NGN-401 gene therapy clinical trial for Rett syndrome. This development marks an important step forward in the quest to address this debilitating neurodevelopmental disorder, which predominantly affects girls and lea...
|
Business Update
Published Sat, Aug 10 2024 7:40 AM UTC
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology firm dedicated to developing transformative genetic therapies for rare neurological disorders, reported its second-quarter financial results for 2024, highlighting key developments that underscore its commitment to improving patient outcomes. The company continues to make significant strides in the field of gene t...
|
Business Update
Published Fri, Aug 9 2024 12:57 PM UTC
Abstract: Neurogene Inc., a clinical-stage biotechnology company focused on developing genetic therapies for rare neurological diseases, has made significant strides in its NGN-401 gene therapy program for Rett syndrome. Recent updates include financial results for the second quarter of 2024 and key milestones in clinical trials. With the company s innovative approaches reco...
|
Per Share |
Current |
Earnings (TTM) |
-3.28 $ |
Revenues (TTM) |
0.05 $
|
Cash Flow (TTM) |
- |
Cash |
8.2 $
|
Book Value |
8.11 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.28 $
|
Revenues (TTM) |
0.05 $ |
Cash Flow (TTM) |
- |
Cash |
8.2 $
|
Book Value |
8.11 $ |
Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com